A sustained beat on consensus forecasts could lift valuations above $1.70, according to sector regression analysis. I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. To that end, you should be aware of the 1 warning sign we've spotted with Clover Health Investments . Additionally, the Centers for Medicare and Medicaid Services (CMS) has upgraded the Star ratings of its Medicare Advantage (MA) plans for 2025, which is a significant factor influencing CMS payments for 2026. Clover Health's emphasis on enhancing healthcare outcomes and its impressive performance in a number of crucial areas are the reasons for this upgrade. CLOV stock forecast is buoyed by policy shifts in Medicare Advantage markets. Analysts project low double-digit percentage growth in memberships, which could influence share price toward $1.70 by year-end if margins improve.